Researchers at Guizhou Medical University have introduced a novel nanoparticle-based method aimed at boosting a promising cancer treatment. The approach utilizes the copper present within tumors to instigate cancer cell death. This study, published in Biomedical Analysis, centers on cuproptosis, a form of cell death triggered when copper disrupts the survival mechanisms of cancer cells.
Cuproptosis has garnered attention for its potential in cancer treatment. However, traditional methods have relied on introducing external copper, raising concerns about toxicity to healthy tissues. To address this issue, the new method delivers a copper-binding agent directly to cancer cells, tapping into copper already inside tumors.
The research team created biodegradable nanoparticles from PLGA-PEG, a material known for its safety and ability to decompose in the body. They modified the nanoparticles’ surface with iRGD, a peptide that guides the particles to cancer cells, and loaded them with TPEN (N,N,N′,N′-tetrakis(2-pyridylmethyl)ethylenediamine), a compound that binds to metal ions like copper.
This formulation, TPEN@1%-iPPN, targets tumor cells specifically. Laboratory tests indicated that the nanoparticles, about 80 nanometers in size, remained stable in conditions mimicking the bloodstream. The particles gradually released their TPEN content over 72 hours, providing prolonged exposure in the tumor environment.
“We have provided a solid proof-of-concept at the cellular level, which we hope will inspire further research into cuproptosis-based nanomedicine,” stated Dr. Ying Chen, the study’s leading author.
Researchers evaluated whether the iRGD coating enhanced the nanoparticles’ cancer-cell targeting ability. In tests with 4T1 breast cancer cells, the targeted nanoparticles showed higher uptake by cancer cells compared to non-targeted ones. A 1% iRGD modification struck a balance between targeting cancer cells and maintaining nanoparticle stability.
The targeted nanoparticles exhibited increased toxicity to 4T1 breast cancer cells while causing less harm to normal human endothelial cells than untargeted TPEN. Dr. Ying Chen emphasized that mobilizing endogenous copper offers a promising path to enhance selectivity, reducing the systemic side effects common in metal-based cancer therapies.
Despite the promising findings, challenges remain before this approach becomes a viable treatment option. Dr. Harshad Kulkarni, chief medical advisor for BAMF Health, noted that while this strategy is scientifically promising, copper-related treatments need to be controllable. Determining which cancers respond best and identifying biomarkers to gauge treatment efficacy are crucial next steps.
Dr. Kulkarni highlighted the importance of ensuring tumor selectivity, as copper is vital for normal cellular functions. Altering copper concentrations could lead to significant toxicity. Future studies must evaluate potential side effects, particularly on major organs, and examine if cancer cells can adapt by modifying copper handling.
Though initially focused on breast cancer, this nanoparticle strategy could apply to other cancer types. Success will likely rely on the biological characteristics of each tumor rather than cancer location. Further research is necessary to translate this laboratory approach into safe and effective patient therapies.